Drug bonded prosthesis and process for producing same

• US 4,879,135 A
• Filed: 07/18/1988
• Issued: 11/07/1989
• Est. Priority Date: 07/23/1984
• Status: Expired due to Fees

• Current Assignee: University of Medicine And Dentistry Of New Jersey
• Original Assignee: University of Medicine and Dentistry of New Jersey (State of New Jersey)
• Inventors: Greco, Ralph S., Trooskin, Stanley Z., Harvey, Richard A.
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): NOT, DEFINED
• Application Number:
  US07/220,503
• Time in Patent Office: 477 Days
• Field of Search: 427/2, 128/334 R, 623/1, 623/12, 623/11, 623/66, 521/30
• US Class Current: 623/1.48
• CPC Class Codes: A61L 2300/254 Enzymes, proenzymes
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence

Abstract

There is disclosed an improved prosthesis coated, respectively, with an anionic surfactant, a drug such as an antibiotic and/or antithrombotic agent. Optionally, the coated prosthesis may be treated with an ion exchange compound, to remove un-drug bound anionic surfactant. The drug is bound directly to the surfactant coated prosthesis.

Claims

1. A prosthesis for use in in vivo surgery having a coating, respectively, of an anionic surfactant and an oppositely charged drug bound to the surfactant.

2. The prosthesis as defined in claim 1 wherein said drug is selected from the group consisting of clindamycin, tobramycin, aminoglycoside, gentamycin, kanamycin and streptomycin.

3. The prosthesis as defined in claim 1 wherein said drug is an antithrombotic drug.

4. The prosthesis as defined in claim 1 wherein said drug is a thrombolytic enzyme.

5. The prosthesis as defined in claim 4 wherein said thrombolytic enzyme is tissue plasminogen activator.

6. The prosthesis as defined in claim 1 wherein said surfactant is a dioctadecylphosphate.

7. The prosthesis as defined in claim 1 wherein said prosthesis is a vascular graft.

8. A method for preparing a prosthesis for use in in vivo surgery, which comprises:

(a) contacting said prosthesis with an anionic surfactant to coat said prosthesis with said surfactant;

(b) contacting said prosthesis of step (a) with a solution of an oppositely charged drug; and

optionally

(c) contacting said prosthesis of step (b) with an appropriate ion exchange compound to remove un-drug bound surfactant.

9. The method as defined in claim 8 wherein the prosthesis of step (a) is washed to remove excess surfactant prior to step (b).

10. The method as defined in claim 8 wherein said prosthesis of step (b) is washed to remove unbound drug compound prior to step (c).

11. The method as defined in claim 9 wherein said prosthesis of step (b) is washed to remove unbound drug compound prior to step (c).

12. The method as defined in claim 8 wherein said surfactant is a dioctadecylphosphate.

13. The method as defined in claim 8 wherein said drug is selected from the group consisting of clindamycin, tobramycin, aminoglycoside, gentamycin, kanamycin and streptomycin.

14. The method as defined in claim 8 wherein said drug is an antithrombotic drug.

15. The method as defined in claim 8 wherein said drug is a thrombolytic enzyme.

16. The method as defined in claim 15 wherein said thrombolytic enzyme is tissue plasminogen activator.

17. The method as defined in claim 8 wherein said ion exchange compound is selected from the group consisting of DEAE-Sepharose--and DEAE-cellulose.